216 related articles for article (PubMed ID: 15613406)
1. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells.
Djouadi F; Aubey F; Schlemmer D; Bastin J
J Clin Endocrinol Metab; 2005 Mar; 90(3):1791-7. PubMed ID: 15613406
[TBL] [Abstract][Full Text] [Related]
2. Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate.
Djouadi F; Bonnefont JP; Thuillier L; Droin V; Khadom N; Munnich A; Bastin J
Pediatr Res; 2003 Oct; 54(4):446-51. PubMed ID: 12840153
[TBL] [Abstract][Full Text] [Related]
3. A new AMPK activator, GSK773, corrects fatty acid oxidation and differentiation defect in CPT2-deficient myotubes.
Boufroura FZ; Le Bachelier C; Tomkiewicz-Raulet C; Schlemmer D; Benoist JF; Grondin P; Lamotte Y; Mirguet O; Mouillet-Richard S; Bastin J; Djouadi F
Hum Mol Genet; 2018 Oct; 27(19):3417-3433. PubMed ID: 30007356
[TBL] [Abstract][Full Text] [Related]
4. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
Djouadi F; Aubey F; Schlemmer D; Ruiter JP; Wanders RJ; Strauss AW; Bastin J
Hum Mol Genet; 2005 Sep; 14(18):2695-703. PubMed ID: 16115821
[TBL] [Abstract][Full Text] [Related]
5. Characterization of L-aminocarnitine, an inhibitor of fatty acid oxidation.
Chegary M; Te Brinke H; Doolaard M; Ijlst L; Wijburg FA; Wanders RJ; Houten SM
Mol Genet Metab; 2008 Apr; 93(4):403-10. PubMed ID: 18077198
[TBL] [Abstract][Full Text] [Related]
6. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts.
Bastin J; Lopes-Costa A; Djouadi F
Hum Mol Genet; 2011 May; 20(10):2048-57. PubMed ID: 21378393
[TBL] [Abstract][Full Text] [Related]
7. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.
Nagasawa T; Inada Y; Nakano S; Tamura T; Takahashi T; Maruyama K; Yamazaki Y; Kuroda J; Shibata N
Eur J Pharmacol; 2006 Apr; 536(1-2):182-91. PubMed ID: 16574099
[TBL] [Abstract][Full Text] [Related]
8. Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.
Coll T; Alvarez-Guardia D; Barroso E; Gómez-Foix AM; Palomer X; Laguna JC; Vázquez-Carrera M
Endocrinology; 2010 Apr; 151(4):1560-9. PubMed ID: 20185762
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency.
Yasuno T; Osafune K; Sakurai H; Asaka I; Tanaka A; Yamaguchi S; Yamada K; Hitomi H; Arai S; Kurose Y; Higaki Y; Sudo M; Ando S; Nakashima H; Saito T; Kaneoka H
Biochem Biophys Res Commun; 2014 May; 448(2):175-81. PubMed ID: 24780397
[TBL] [Abstract][Full Text] [Related]
10. Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs?
Djouadi F; Aubey F; Schlemmer D; Gobin S; Laforet P; Wanders RJ; Strauss AW; Bonnefont JP; Bastin J
J Inherit Metab Dis; 2006; 29(2-3):341-2. PubMed ID: 16763897
[TBL] [Abstract][Full Text] [Related]
11. Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay.
Yamaguchi S; Li H; Purevsuren J; Yamada K; Furui M; Takahashi T; Mushimoto Y; Kobayashi H; Hasegawa Y; Taketani T; Fukao T; Fukuda S
Mol Genet Metab; 2012 Sep; 107(1-2):87-91. PubMed ID: 22841441
[TBL] [Abstract][Full Text] [Related]
12. Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes.
Watt MJ; Southgate RJ; Holmes AG; Febbraio MA
J Mol Endocrinol; 2004 Oct; 33(2):533-44. PubMed ID: 15525607
[TBL] [Abstract][Full Text] [Related]
13. Carnitine-acylcarnitine translocase deficiency: Two neonatal cases with common splicing mutation and in vitro bezafibrate response.
Vatanavicharn N; Yamada K; Aoyama Y; Fukao T; Densupsoontorn N; Jirapinyo P; Sathienkijkanchai A; Yamaguchi S; Wasant P
Brain Dev; 2015 Aug; 37(7):698-703. PubMed ID: 25459972
[TBL] [Abstract][Full Text] [Related]
14. Combination of lipid metabolism alterations and their sensitivity to inflammatory cytokines in human lipin-1-deficient myoblasts.
Michot C; Mamoune A; Vamecq J; Viou MT; Hsieh LS; Testet E; Lainé J; Hubert L; Dessein AF; Fontaine M; Ottolenghi C; Fouillen L; Nadra K; Blanc E; Bastin J; Candon S; Pende M; Munnich A; Smahi A; Djouadi F; Carman GM; Romero N; de Keyzer Y; de Lonlay P
Biochim Biophys Acta; 2013 Dec; 1832(12):2103-14. PubMed ID: 23928362
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency.
Bonnefont JP; Bastin J; Laforêt P; Aubey F; Mogenet A; Romano S; Ricquier D; Gobin-Limballe S; Vassault A; Behin A; Eymard B; Bresson JL; Djouadi F
Clin Pharmacol Ther; 2010 Jul; 88(1):101-8. PubMed ID: 20505667
[TBL] [Abstract][Full Text] [Related]
16. Carbacyclin induces carnitine palmitoyltransferase-1 in cardiomyocytes via peroxisome proliferator-activated receptor (PPAR) delta independent of the IP receptor signaling pathway.
Kuroda T; Hirota H; Fujio Y; Sugiyama S; Masaki M; Hiramoto Y; Shioyama W; Okamoto K; Hori M; Yamauchi-Takihara K
J Mol Cell Cardiol; 2007 Jul; 43(1):54-62. PubMed ID: 17540403
[TBL] [Abstract][Full Text] [Related]
17. Peroxisomes contribute to the acylcarnitine production when the carnitine shuttle is deficient.
Violante S; Ijlst L; Te Brinke H; Koster J; Tavares de Almeida I; Wanders RJ; Ventura FV; Houten SM
Biochim Biophys Acta; 2013 Sep; 1831(9):1467-74. PubMed ID: 23850792
[TBL] [Abstract][Full Text] [Related]
18. Effect of heat stress and bezafibrate on mitochondrial beta-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay.
Li H; Fukuda S; Hasegawa Y; Kobayashi H; Purevsuren J; Mushimoto Y; Yamaguchi S
Brain Dev; 2010 May; 32(5):362-70. PubMed ID: 19589653
[TBL] [Abstract][Full Text] [Related]
19. Bezafibrate upregulates carnitine palmitoyltransferase II expression and promotes mitochondrial energy crisis dissipation in fibroblasts of patients with influenza-associated encephalopathy.
Yao M; Yao D; Yamaguchi M; Chida J; Yao D; Kido H
Mol Genet Metab; 2011 Nov; 104(3):265-72. PubMed ID: 21816645
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol-Induced Changes in MicroRNA Expression in Primary Human Fibroblasts Harboring Carnitine-Palmitoyl Transferase-2 Gene Mutation, Leading to Fatty Acid Oxidation Deficiency.
Aires V; Delmas D; Djouadi F; Bastin J; Cherkaoui-Malki M; Latruffe N
Molecules; 2017 Dec; 23(1):. PubMed ID: 29271911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
